Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL98696 | 0.88 | ALDH1A1 (0.53) | ALDH1A1MAPTHPGDLMNAPOLB | |
| SCHEMBL98697 | 0.88 | ALDH1A1 (0.53) | ALDH1A1MAPTHPGDLMNAPOLB | |
| SCHEMBL1620970 | 0.85 | ALDH1A1 (0.41) | ALDH1A1MAPTKDM4EAPOBEC3GHPGD | |
| SCHEMBL100696 | 0.76 | CCNE2 (0.44) | ALDH1A1MAPTKDM4EHPGDPOLB | |
| SCHEMBL100695 | 0.76 | CCNE2 (0.44) | ALDH1A1MAPTKDM4EHPGDPOLB | |
| SCHEMBL1619293 | 0.76 | ALDH1A1 (0.35) | ALDH1A1MAPTKDM4EAPOBEC3GHPGD | |
| SCHEMBL98261 | 0.76 | GAA (0.36) | ALDH1A1MAPTLMNACYP1A2CYP2C19 | |
| SCHEMBL98779 | 0.76 | GAA (0.36) | ALDH1A1MAPTLMNACYP1A2CYP2C19 | |
| SCHEMBL1679746 | 0.75 | ALDH1A1 (0.34) | ALDH1A1MAPTKDM4EHPGDLMNA | |
| SCHEMBL1620825 | 0.74 | ALDH1A1 (0.33) | ALDH1A1MAPTHPGDLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9132130-B2 | Purine derivative and antitumor agent using same | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2015-09-15 | — | — | US | disclosed |
| US-20120088765-A1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088765-A1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | PNP, TYMP, DPYD | ALDH1A1 336/4885MAPT 4571/4885KDM4E 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.